Shilpa Medicare Valuation
Is SHILPAMED undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SHILPAMED when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SHILPAMED (₹894.55) is trading above our estimate of fair value (₹64.61)
Significantly Below Fair Value: SHILPAMED is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SHILPAMED?
Key metric: As SHILPAMED is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is SHILPAMED's PE Ratio? | |
|---|---|
| PE Ratio | 126.9x |
| Earnings | ₹610.83m |
| Market Cap | ₹77.52b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.8x |
| Enterprise Value/EBITDA | 28.8x |
| PEG Ratio | 1.6x |
Price to Earnings Ratio vs Peers
How does SHILPAMED's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 40.1x | ||
500126 Procter & Gamble Health | 39.7x | 11.3% | ₹86.3b |
531599 FDC | 26.3x | n/a | ₹83.2b |
SUPRIYA Supriya Lifescience | 40.3x | 14.3% | ₹63.4b |
BLUEJET Blue Jet Healthcare | 54x | 24.1% | ₹90.7b |
SHILPAMED Shilpa Medicare | 126.9x | 77.1% | ₹77.5b |
Price-To-Earnings vs Peers: SHILPAMED is expensive based on its Price-To-Earnings Ratio (126.9x) compared to the peer average (40.1x).
Price to Earnings Ratio vs Industry
How does SHILPAMED's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
INDSWFTLAB Ind-Swift Laboratories | 1.5x | n/a | US$66.29m |
524652 Ind-Swift | 2.1x | n/a | US$13.37m |
| 2 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: SHILPAMED is expensive based on its Price-To-Earnings Ratio (126.9x) compared to the Indian Pharmaceuticals industry average (34.2x).
Price to Earnings Ratio vs Fair Ratio
What is SHILPAMED's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 126.9x |
| Fair PE Ratio | 91.6x |
Price-To-Earnings vs Fair Ratio: SHILPAMED is expensive based on its Price-To-Earnings Ratio (126.9x) compared to the estimated Fair Price-To-Earnings Ratio (91.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ₹894.55 | ₹1,208.00 +35.0% | 26.2% | ₹1,525.00 | ₹891.00 | n/a | 2 |
| Nov ’25 | ₹842.75 | ₹1,095.50 +30.0% | 18.7% | ₹1,300.00 | ₹891.00 | n/a | 2 |
| Oct ’25 | ₹835.70 | ₹1,095.50 +31.1% | 18.7% | ₹1,300.00 | ₹891.00 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Vivimed Labs
₹410.4m
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.
VIVIMEDLAB
₹4.95
7D
0%
1Y
-45.9%
Sanofi India
₹142.5b
Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.
SANOFI
₹6,197.45
7D
0.8%
1Y
-23.0%
Novartis India
₹26.1b
Operates as a healthcare company in India.
500672
₹1,058.30
7D
3.5%
1Y
52.4%